Ascendis Pharma AS (BSP:A1SN34)
R$ 48.84 0 (0%) Market Cap: 2.92 Bil Enterprise Value: 5.48 Bil PE Ratio: 0 PB Ratio: 0 GF Score: 64/100

Ascendis Pharma A/S - Special Call Transcript

Mar 04, 2019 / 01:00PM GMT
Operator

Good day, ladies and gentlemen, and welcome to the Phase III heiGHt Trial Results Conference Call. At this time, all participants are in a listen-only mode. (Operator Instructions) As a reminder, this conference call may be recorded.

I would now like to introduce your host for today's conference, Mr. Scott Smith, CFO. Sir, you may begin.

Scott T. Smith;S;CFO
Ascendis Pharma A;Senior VP & Member of Executive Board

/- -

Thank you, operator. Thank you, everyone for joining our call today. I'm Scott Smith, Chief Financial Officer of Ascendis. Joining me on the call today are Jan Mikkelsen, President and Chief Executive Officer; and Dr. Jonathan Leff, Chief Medical Officer.

Before we begin, I would like to remind you that this conference call will contain forward-looking statements that are intended to be covered under the Safe Harbor, provided by the Private Securities Litigation Reform Act. Examples of such statements may include, but are not limited to: our progress on our pipeline candidates and our

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot